Content Library

AAV Durability: The Road to a One-Shot Cure

Inconsistent long-term clinical data has highlighted the need to better understand the durability of AAV gene therapy.

Hanson Wade Intelligence's Market Research division have classified 121 AAV gene therapy trials into 4 distinct groups based on the target tissue type – liver, muscle, CNS and ocular tissues. This allowed us to summarise available data on clinical durability as well as the key findings we observed across tissues, trials, doses and serotypes.

We hope that this report will provide gene therapy developers with valuable insights on the durability of the current generation of AAV gene therapies.  

Gene Therapy Trial Landscape in 2020

Screenshot 2021-01-19 113545

Gene Therapy Drug Landscape in 2020

GT US RD 2021 Insights-Preclincial assets

Gene Therapy for Rare Disorders Europe Past Presentations

GMO Requirements

GMO Requirements for Gene Therapies in Europe Latest Developments

Annie Hubert, Senior Director, European Public Policy

Ocugen Report

The Importance of Strategic Partnerships in Gene Therapy

Dr. Shankar Musunuri, Chairman, CEO & Co Founder, Ocugen, Inc.